| Name | AAPK-25 |
| Description | AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, causing mitotic delay and arresting cells in prometaphase, followed by increased apoptosis. It targets Aurora-A/-B/-C with Kd values ranging from 23-289 nM. |
| In vitro | AAPK-25 inhibits the growth of HCT-116, Calu6, A549, and MCF-7 cells (IC50s: 0.4, 5.3, 11.6, and 2.3 μM). It induces apoptosis in a dose-dependent manner in the HCT-116 cell line, significantly increases histone H3Ser10 phosphorylation, indicating a marked mitotic block, and notably inhibits the mitotic spindle checkpoint. |
| In vivo | AAPK-25 enhances the survival rate in the BALB/c nude mice tumor xenograft model. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (113.04 mM)
|
| Keywords | Aurora Kinase | AAPK 25 | inhibit | Polo-like Kinase (PLK) | AAPK25 | Apoptosis | Inhibitor | AAPK-25 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
